John J. Renger Ph.D.
Net Worth

Last updated:

What is John J. Renger Ph.D. net worth?

The estimated net worth of Dr. John J. Renger Ph.D. is at least $19,912,903 as of 7 Feb 2024. He has earned $16,132,583 from insider trading and has received compensation worth at least $3,780,320 in Cerevel Therapeutics Holdings, Inc..

What is the salary of John J. Renger Ph.D.?

Dr. John J. Renger Ph.D. salary is $945,080 per year as Chief Scientific Officer in Cerevel Therapeutics Holdings, Inc..

How old is John J. Renger Ph.D.?

Dr. John J. Renger Ph.D. is 56 years old, born in 1969.

What stocks does John J. Renger Ph.D. currently own?

As insider, Dr. John J. Renger Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Cerevel Therapeutics Holdings, Inc. (CERE) Chief Scientific Officer 6,370 $0 $0

What does Cerevel Therapeutics Holdings, Inc. do?

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

CERE logo
CERE
Cerevel Therapeutics Holdings, Inc.

John J. Renger Ph.D. insider trading

Cerevel Therapeutics Holdings, Inc.

Dr. John J. Renger Ph.D. has made 29 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 2,161 units of CERE stock worth $89,777 on 7 Feb 2024.

The largest trade he's ever made was exercising 55,000 units of CERE stock on 10 Nov 2021. As of 7 Feb 2024 he still owns at least 6,370 units of CERE stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 2,161 $41.54 $89,777
Option
Common Stock 5,020 N/A N/A
Option
Restricted Stock Units 5,020 N/A N/A
Sale
Common Stock 25,000 $30 $750,000
Option
Stock Option (Right to Buy) 14,982 $10.28 $154,015
Option
Stock Option (Right to Buy) 10,018 $3.5 $35,063
Option
Common Stock 14,982 $10.28 $154,015
Option
Common Stock 10,018 $3.5 $35,063
Option
Stock Option (Right to Buy) 10,018 $3.5 $35,063
Sale
Common Stock 25,000 $30 $750,000
Option
Common Stock 10,018 $3.5 $35,063
Option
Stock Option (Right to Buy) 14,982 $10.28 $154,015
Option
Common Stock 14,982 $10.28 $154,015
Sale
Common Stock 36,141 $40.19 $1,452,543
Option
Stock Option (Right to Buy) 25,376 $10.28 $260,865
Option
Common Stock 25,376 $10.28 $260,865
Option
Stock Option (Right to Buy) 29,624 $3.5 $103,684
Sale
Common Stock 18,859 $41.1 $775,086
Option
Common Stock 29,624 $3.5 $103,684
Option
Stock Option (Right to Buy) 10,000 $3.5 $35,000
Option
Common Stock 10,000 $3.5 $35,000
Option
Stock Option (Right to Buy) 20,000 $3.5 $70,000
Sale
Common Stock 10,000 $37.75 $377,500
Sale
Common Stock 20,000 $32.5 $650,000
Option
Common Stock 20,000 $3.5 $70,000
Option
Common Stock 25,000 $3.5 $87,500
Option
Stock Option (Right to Buy) 25,000 $3.5 $87,500
Sale
Common Stock 25,000 $30 $750,000
Option
Common Stock 1,105 $3.5 $3,868
Sale
Common Stock 1,105 $32.5 $35,913
Option
Stock Option (Right to Buy) 1,105 $3.5 $3,868
Option
Stock Option (Right to Buy) 25,000 $3.5 $87,500
Sale
Common Stock 25,000 $30 $750,000
Option
Common Stock 25,000 $3.5 $87,500
Option
Common Stock 45,000 $3.5 $157,500
Option
Stock Option (Right to Buy) 45,000 $3.5 $157,500
Sale
Common Stock 45,000 $34.65 $1,559,115
Option
Stock Option (Right to Buy) 10,000 $3.5 $35,000
Sale
Common Stock 10,000 $35 $350,000
Option
Common Stock 10,000 $3.5 $35,000
Option
Stock Option (Right to Buy) 20,000 $3.5 $70,000
Option
Common Stock 20,000 $3.5 $70,000
Option
Stock Option (Right to Buy) 25,000 $3.5 $87,500
Sale
Common Stock 20,000 $32.5 $650,000
Option
Common Stock 25,000 $3.5 $87,500
Sale
Common Stock 25,000 $30 $750,000
Sale
Common Stock 10,000 $35 $350,000
Sale
Common Stock 20,000 $32.5 $650,000
Option
Common Stock 30,000 $3.5 $105,000
Option
Stock Option (Right to Buy) 30,000 $3.5 $105,000
Option
Stock Option (Right to Buy) 25,000 $3.5 $87,500
Sale
Common Stock 25,000 $30 $750,000
Option
Common Stock 25,000 $3.5 $87,500
Option
Common Stock 25,000 $3.5 $87,500
Option
Stock Option (Right to Buy) 25,000 $3.5 $87,500
Sale
Common Stock 25,000 $30 $750,000
Option
Stock Option (Right to Buy) 5,873 $3.5 $20,556
Option
Stock Option (Right to Buy) 4,127 $3.5 $14,445
Sale
Common Stock 4,127 $35 $144,445
Option
Common Stock 4,127 $3.5 $14,445
Option
Common Stock 5,873 $3.5 $20,556
Sale
Common Stock 5,873 $35.01 $205,584
Option
Stock Option (Right to Buy) 7,300 $3.5 $25,550
Sale
Common Stock 7,300 $32.5 $237,250
Option
Common Stock 7,300 $3.5 $25,550
Option
Stock Option (Right to Buy) 5,578 $3.5 $19,523
Option
Common Stock 7,122 $3.5 $24,927
Sale
Common Stock 7,122 $32.5 $231,465
Option
Stock Option (Right to Buy) 25,000 $3.5 $87,500
Option
Stock Option (Right to Buy) 7,122 $3.5 $24,927
Option
Common Stock 5,578 $3.5 $19,523
Sale
Common Stock 5,578 $32.5 $181,285
Sale
Common Stock 25,000 $30.02 $750,450
Option
Common Stock 25,000 $3.5 $87,500
Sale
Common Stock 13,140 $41.44 $544,482
Option
Common Stock 55,000 $3.5 $192,500
Sale
Common Stock 23,632 $38.59 $911,935
Sale
Common Stock 10,030 $40.41 $405,332
Sale
Common Stock 6,135 $39.61 $243,001
Option
Stock Option (Right to Buy) 55,000 $3.5 $192,500
Sale
Common Stock 2,063 $42.38 $87,420

Cerevel Therapeutics Holdings key executives

Cerevel Therapeutics Holdings, Inc. executives and other stock owners filed with the SEC: